COMMUNIQUÉS West-GlobeNewswire

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
20/10/2025
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- [...]
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU
20/10/2025
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One ® Robotic HIFU Lyon, France – October 20, 2025 – EDAP TMS SA (Nasdaq: EDAP) (“EDAP” or the “Company”) , a global [...]
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
20/10/2025
Detailed results from bezuclastinib’s positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this year NDA submission [...]
SARMs RAD 140 (Testolone) and IBUTAMOREN MK-677 SARMS Stack: Crazy Bulk Lunch Rad 140 Effective Sarms for Bulking and Muscle Growth in 2025
20/10/2025
Read about Crazybulk SARMs Rad 140 (Testolone) Rad 140 Benefits and Side Effects, What Is Rad 140, Rad 140 Cycle, Rad 140 PCT, How To Take Rad 140 Sarms NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- NEW YORK, Oct 18, 2025 [...]
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
20/10/2025
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing development of PALI [...]
OneMedNet Welcomes Our Latest Subscriber mlHealth360
20/10/2025
MINNEAPOLIS, Oct. 20, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced today that mlHealth360, a healthcare AI and [...]
AAMI and TechNation Collaborate to Survey HTM Field
20/10/2025
Survey will assess demographics, salary rates, more Arlington, Virginia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Soon, the health technology community will have fresh insights and previously unknown data about some of its [...]
Avance Clinical Launches Dedicated Center of Excellence to Accelerate Early Phase Biotech Trials
20/10/2025
ADELAIDE, Australia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Avance Clinical , the Australia-based global CRO partner for biotechs, has been a leader in early phase clinical research for more than 30 years. With operations [...]
VitalHub Announces Q3 2025 Conference Call Date
20/10/2025
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the "Company" or "VitalHub") announced today that it will release financial results for its third quarter 2025 ended September 30, 2025 [...]
ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025
20/10/2025
SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial [...]
Eleos to Launch Polaris AI Advanced, Purpose-Built Foundational AI Model for Post-Acute Care, built with Google Cloud Technology
20/10/2025
Polaris AI leverages Google Cloud’s Gemini family of multimodal models and Eleos’ secure and clinically validated infrastructure to reduce documentation burden, strengthen compliance and help providers focus on care. [...]
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
20/10/2025
OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit , taking place October 22-23, 2025 in [...]
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conference call on 4 Nov 2025 at 11.00 CET
20/10/2025
Tuesday, 4 November 2025 at 11:00 - 12:00am CET In connection with the publication of Coloplast’s interim financial results for FY 2024/25, to be released same day around 07.00am CET, Coloplast will host a conference [...]
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
20/10/2025
– Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including pain, compared to [...]
Angelini Ventures Deepens Commitment to CoMind, a Neurotech Redefining Brain Monitoring, with Participation in $60 Million Round Bringing Total Funding to $102.5 Million
20/10/2025
CoMind's optical brain sensing technology uses laser light delivered through a removable sensor to provide continuous, non-invasive brain monitoring without need for surgery Advancing brain health is a strategic [...]
Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for AIC468 at ID Week 2025
20/10/2025
Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnet Pritelivir Phase 2 results supported FDA Breakthrough Therapy Designation and [...]
The Ensign Group Schedules Third Quarter Earnings Call for Tuesday, November 4, 2025
20/10/2025
SAN JUAN CAPISTRANO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025
20/10/2025
LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30 [...]
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
20/10/2025
LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]

Pages